Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.

Tislelizumab can cause cutaneous lupus erythematosus.

Alitretinoin may help treat alopecia areata.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

Ruxolitinib can help regrow hair in severe alopecia areata.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Madam C.J. Walker became the first self-made female millionaire in the USA by creating a successful hair care product for Black women.

A child with skin and tooth symptoms was found to have a genetic mutation causing cardiocutaneous syndrome, leading to heart problems.

Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Stopping methotrexate might reverse lymphoma-like conditions in some patients.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Deucravacitinib may effectively treat discoid lupus erythematosus.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

Infliximab improved skin and bowel symptoms in Crohn's disease but caused side effects and the disease returned after stopping treatment.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.